DrugPatentWatch Archives

You are currently viewing the 2010 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: milnacipran hydrochloride

Summary for Generic Name: milnacipran hydrochloride

Drug Master File Entries: see list15
Suppliers: see list7

Pharmacology for Ingredient: milnacipran hydrochloride

Clinical Trials for: milnacipran hydrochloride

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)
Status: Terminated Condition: Irritable Bowel Syndrome

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Status: Recruiting Condition: Sleep Disorders; Fibromyalgia; Sleep

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia
Status: Completed Condition: Fibromyalgia

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis
Status: Completed Condition: Arthritis, Rheumatoid

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran
Status: Recruiting Condition: Back Pain

Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis
Status: Recruiting Condition: Osteoarthritis

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia
Status: Completed Condition: Fibromyalgia

Milnacipran for Chronic Pain in Knee Osteoarthritis
Status: Completed Condition: Knee Osteoarthritis; Degenerative Joint Disease; Chronic Pain

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients
Status: Recruiting Condition: Systemic Lupus Erythematosus; Widespread Pain; Fibromyalgia

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial
Status: Completed Condition: Fibromyalgia; Neurocognition

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cypress Bioscience
milnacipran hydrochloride
TABLET; ORAL022256Jan 14, 2009RXYes6,602,911<disabled>MANAGEMENT OF FIBROMYALGIA (FM)
Cypress Bioscience
milnacipran hydrochloride
TABLET; ORAL022256Jan 14, 2009RXYes6,992,110<disabled>MANAGEMENT OF FIBROMYALGIA (FM)
Cypress Bioscience
milnacipran hydrochloride
TABLET; ORAL022256Jan 14, 2009RXYes<disabled>NEW CHEMICAL ENTITY
Cypress Bioscience
milnacipran hydrochloride
TABLET; ORAL022256Jan 14, 2009RXNo6,602,911<disabled>MANAGEMENT OF FIBROMYALGIA (FM)
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology